# A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

> **NCT03301220** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 390 (actual)

## Conditions studied

- Smoldering Multiple Myeloma

## Interventions

- **DRUG:** Daratumumab SC: daratumumab + rHuPH20

## Key facts

- **NCT ID:** NCT03301220
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-07
- **Primary completion:** 2024-05-01
- **Final completion:** 2026-06-30
- **Target enrollment:** 390 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301220, "A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03301220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*